Zoetis Inc. $ZTS Shares Sold by Walter Public Investments Inc.

Walter Public Investments Inc. decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 21.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 41,039 shares of the company’s stock after selling 10,941 shares during the quarter. Walter Public Investments Inc.’s holdings in Zoetis were worth $4,851,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP grew its position in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares in the last quarter. State Street Corp grew its position in shares of Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after acquiring an additional 149,382 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $734,425,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Morgan Stanley reissued an “overweight” rating and set a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Citigroup decreased their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $126.92.

Zoetis Stock Performance

Shares of ZTS opened at $74.73 on Friday. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $161.77. The company has a market cap of $31.33 billion, a price-to-earnings ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a fifty day moving average of $84.04 and a 200-day moving average of $109.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is currently 35.16%.

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.